Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Rapid Agglutination Latex Test Developed for Diarrheagenic Pathogens

By LabMedica International staff writers
Posted on 08 Oct 2014
Enteropathogenic and enterohemorrhagic Escherichia coli (EPEC/EHEC) are human intestinal pathogens responsible for diarrhea in both developing and industrialized countries.

A rapid and simple assay for EPEC/EHEC detection has been developed using the EPEC/EHEC-secreted proteins EspA and EspB, which were chosen as target antigens since they are the major secreted proteins in both pathogens.

Bacteriologists at the Instituto Butantan (São Paulo, Brazil) analyzed 71 atypical EPEC (aEPEC), 31 typical EPEC (tEPEC), and 23 EHEC belonging to different serotypes characterized as locus of enterocyte effacement (LEE)-positive isolates. More...
The secreted proteins EspA and EspB were detected using an enzyme linked immunosorbent assay and the absorbance was measured at 492 nm in a Multiskan EX ELISA reader (Thermo Scientific; Waltham, MA, USA).

For rapid agglutination latex test (RALT), bacterial isolates were grown on Dulbecco’s modified Eagle’s medium (DMEM)-agar and the tests were done using latex sensitized with anti-EspB monoclonal antibody (MAb). The RALT was performed on a slide glass using 20 µL of bacterial lysate and 20 µL of latex beads coupled to anti-EspB (MAb), and checking for agglutination after five minutes of gentle mixing. The EspB secreted protein was defined as a biomarker and its corresponding monoclonal antibody as the tool for EPEC/EHEC diagnosis; the production of EspB was better in DMEM medium.

The indirect ELISA using anti-EspB MAb showed 90.4% sensitivity and 96.4%, specificity, indicating its possible use in routine diagnostic laboratories. However, this methodology requires specific laboratory instrumentation, making it difficult to be performed in low-income country settings. The RALT assay can be considered an alternative assay for diarrhea diagnosis in low-income countries since it achieved 97% sensitivity, 98% specificity and 97% efficiency. RALT assay has the sensitivity and specificity required for high-impact diagnosis of neglected diseases in the developing world.

The authors concluded that serotyping-based diagnosis is the only methodology available in limited-resources settings, employing either commercial or in-house antisera. The standardized RALT for detection of EPEC and EHEC will have a remarkable impact in the diagnosis of these pathotypes, as the established agglutination latex test is a simple, rapid and easy to perform test, which can be employed in less equipped laboratories in low-income countries. The study was published on September 25, 2014, in the Public Library of Science Neglected Tropical Diseases.

Related Links:

Instituto Butantan 
Thermo Scientific



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
hCG Whole Blood Pregnancy Test
VEDALAB hCG-CHECK-1
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.